{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:49:09Z","timestamp":1794019749922,"version":"4.8.0"},"reference-count":17,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Bova Compounding"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Feline Medicine and Surgery"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Current antiviral therapy for feline infectious peritonitis (FIP) has limited availability and can be cost-prohibitive. The nucleoside analogue EIDD-1931 is an effective inhibitor against FIP virus serotype I and II in vitro. Our objective was to determine whether EIDD-1931 is an effective treatment option for cats with naturally occurring FIP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective clinical trial was conducted with nine client-owned cats diagnosed with effusive or non-effusive FIP including neurological involvement. Cats were administered EIDD-1931 orally twice daily for 12 weeks. A complete response was defined as resolution of all abnormalities associated with FIP. Clinical variables, haematology, biochemistry and imaging findings were monitored during treatment and after discontinuing treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six cats with effusive FIP and three cats with non-effusive FIP (median age 1.0 year, range 0.5\u20137.9) were treated with EIDD-1931 (median dose 16.2\u2009mg\/kg PO q12h, range 12.0\u201320.5) for 12 weeks in eight cats and 14 weeks in one cat. All cats showed a complete response to treatment. Adverse effects included transient neutropenia (three cats), elevated alanine transaminase (transient in three cats, persistent in one cat), broken whiskers (one cat) and suspected treatment-induced relative hyporexia (six cats). Adverse effects were not dose dependent. Follow-up was available for more than 12 months after treatment discontinuation. One cat relapsed on two occasions, responding to repeat treatment at escalating dosages before subsequent development of treatment-resistant lymphoma, resulting in euthanasia 545 days after study enrolment. No other relapse events or diseases were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>EIDD-1931 administered at 15\u201320\u2009mg\/kg PO q12h for 12 weeks is a feasible treatment option for naturally occurring FIP. Adverse effects may be more common than treatment with GS-441524.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1098612x261420870","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T03:51:23Z","timestamp":1769658683000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Nucleoside analogue EIDD-1931 in the treatment of naturally occurring feline infectious peritonitis"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4596-1812","authenticated-orcid":false,"given":"Alexandra","family":"Kennedy","sequence":"first","affiliation":[{"name":"Small Animal Specialist Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"White","sequence":"additional","affiliation":[{"name":"Small Animal Specialist Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/v15091847"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X231194460"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.16804"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.16803"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11101209"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2024.1377207"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/v14112429"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.17187"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.16832"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X221118761"},{"key":"e_1_3_2_12_2","unstructured":"Bova Aus. BOVA \u2013 veterinary pharmaceuticals. Veterinary Specials. BOVA GLOBAL. https:\/\/bova.vet\/bova-aus\/quality-assured\/ (2023 accessed 20 November 2025)."},{"key":"e_1_3_2_13_2","unstructured":"World Small Animal Veterinary Association. WSAVA body condition score. https:\/\/wsava.org\/wp-content\/uploads\/2020\/08\/Body-Condition-Score-cat-updated-August-2020.pdf (2020 accessed 10 October 2025)."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X12441875"},{"key":"e_1_3_2_15_2","unstructured":"PubChem. Molnupiravir. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/145996610 (2025 accessed 14 November 2025)."},{"key":"e_1_3_2_16_2","unstructured":"PubChem. N4-Hydroxycytidine. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/197020 (2025 accessed 14 November 2025)."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/v16071144"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X211048647"}],"container-title":["Journal of Feline Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1098612X261420870","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1098612X261420870","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1098612X261420870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:12:48Z","timestamp":1777500768000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1098612X261420870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/1098612X261420870"],"URL":"https:\/\/doi.org\/10.1177\/1098612x261420870","relation":{},"ISSN":["1098-612X","1532-2750"],"issn-type":[{"value":"1098-612X","type":"print"},{"value":"1532-2750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"article-number":"1098612X261420870"}}